Sun Of India Agrees With Sanofi Of France To Delay Marketing Generic
This article was originally published in PharmAsia News
Executive Summary
India's Sun Pharmaceutical Industries reached an agreement with Sanofi-Aventis to settle a U.S. case by ceasing to sell a generic of a cancer drug after June 30